BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Aldesleukin 22 million units (1.3 mg) (SteriMax) (F)(PFL) no preservative[1]	1.2 mL SWI[1] direct diluent against side of vial during reconstitution[1] do NOT shake[1]	18 million unit/mL (1.1 mg/mL)[1]	12 h **F**, RT[1,2]	30-70 mcg/mL[1] 50 mL D5W[1] <30 mcg/mL: dilute in D5W containing human albumin 0.1%[3]	48 h **F**, RT[1] bring to RT prior to use[1]	- do NOT use in-line filter[1] - avoid bacteriostatic water for injection or NS due to increased aggregation[1]
				SC syringe[4,5]	10 d F[2,5] **(PFL)	
Aldesleukin **<u>intralesional</u>** 22 million units (1.3 mg) (SteriMax) (F)(PFL) no preservative[1]	1.2 mL SWI[1] direct diluent against side of vial during reconstitution[1] do NOT shake[1]	18 million unit/mL (1.1 mg/mL)[1]	12 h **F**, RT[1,2]	add 3.2 mL D5W to reconstituted vial to give 5 million units/mL[6,7] withdraw entire contents of vial into syringes for administration[6,7]	syringe: 48 h F[6] (discard any remaining unused syringes following procedure)	- avoid bacteriostatic water for injection or NS due to increased aggregation[1]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Alemtuzumab 30 mg/mL (Genzyme/Bayer)[8] (F)(PFL) do not shake no preservative[9]	N/A	filter NOT required[9] 30 mg/mL[9]	discard unused portion[9]	SC syringe[10]	discard at the end of the day **F,** RT	- do NOT shake[11]
				100 mL **NS,** D5W[9]	8 h **F,** RT[9]** (PFL)[11]	
Amivantamab (JNJ-61186372)[12,13] 350 mg (Janssen) (F)(PFL) no preservative[14] (SAP)	N/A	50 mg/mL	discard unused portion[14]	250 mL **NS**, D5W[14] dilute to final volume by withdrawing volume from bag equal to volume of drug to be added[14] mix by gentle inversion[14]	complete administration within 10 h RT[14]	- do not shake[14] - discard if discolouration or visible particles are present[14] - administer with 0.2 micron in-line filter[14]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Amivantamab 350 mg (Janssen) (F)(PFL) no preservative[15]	N/A	50 mg/mL[15]	discard unused portion[15]	250 mL **NS**, D5W[15] dilute to final volume by withdrawing volume from bag equal to volume of drug to be added[15] mix by gentle inversion; do not shake[15]	complete administration within 10 h RT[15]	- each vial contains 0.5 mL overfill[15] - discard if discolouration or visible particles are present[15] - administer with 0.2 micron in-line filter[15]
Amsacrine 75 mg/1.5 mL (Erfa Canada) (RT) no preservative[16]	glass syringes preferred for reconstitution; MAX time in plastic syringe[16]: 15 min 13.5 mL supplied diluent (L-lactic acid)[1] to reconstitute: transfer 1.5 mL from ampoule into the diluent vial[16]	5 mg/mL[16]	12 h RT[2,16] **(PFL)[16]	500 mL D5W[16] (plastic or glass container)[16]	7 d **F**, 4 d RT[2,16]	- contains DMA***

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Arsenic trioxide 10 mg/10 mL (Phebra/ICON) (RT) no preservative[17]	N/A	1 mg/mL[17]	discard unused portion[17]	100-250 mL **NS**, D5W[17]	48 h F**,** 24 h RT[17]	
Arsenic trioxide 10 mg/10 mL (Sandoz) (RT) no preservative[18]	N/A	1 mg/mL[18]	discard unused portion[18]	100-250 mL **NS**, D5W[18]	48 h F**,** 24 h RT[18]	
Arsenic trioxide 10 mg/10 mL (SteriMax) (RT) no preservative[19]	N/A	1 mg/mL[19]	discard unused portion[19]	100-250 mL **NS**, D5W[19]	48 h F**,** 24 h RT[19]	

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Asparaginase-erwinia (asparaginase *Erwinia chrysanthemi*) 10,000 units (CGF/Jazz) (F) no preservative[20]	1-2 mL NS[20] do not shake; mix gently to minimize bubbles and contact with stopper[20]	10,000-5000 units/mL	15 min RT[20]	syringe[20]	4 h RT[20]	- contact with the rubber stopper may denature the reconstituted drug, creating filaments of insoluble material; if present, administer with 5 micron filter[20] - do not use sterile water for reconstitution as the resulting product is not isotonic[20]
PEG-asparaginase - see pegaspargase in L-Z chart (pegylated asparaginase *E. coli*)						
Atezolizumab 840 mg/14 mL 1200 mg/20 mL (Hoffman-La Roche) (F)(PFL) do not shake no preservative[21]	N/A	60 mg/mL[21]	discard unused portion[21]	250 mL NS[21] mix by gentle inversion[21]	24 h F, 8 h RT[21]	- do NOT shake[21]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Avelumab 200 mg/10 mL (EMD) (F)(PFL) no preservative[22]	N/A	20 mg/mL[22]	discard unused portion[23]	250 mL **NS**, ½-NS[22] mix by gentle inversion[22]	complete administration within 24 h F, 8 h RT[22] if refrigerated, bring bag to RT prior to administration[22]	- do NOT shake[22] - administer with 0.2 micron in-line filter[22]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
azaCITIDine 100 mg (Celgene) (RT) no preservative[24]	4 mL SWI[24] shake vigorously[24] record time of reconstitution	25 mg/mL[24]	use within 45 min RT or 8 h F[24]	SC syringe[24]	45 min RT (including preparation time) or 8 h F[24] refrigerate syringe immediately after preparation if not to be used within 45 min of reconstitution[24] **Refrigerated syringes**[24]: • allow up to 30 min prior to administration to reach temperature of ~20-25°C • discard syringe if time elapsed at RT is greater than 30 min	- discard if contains large particles[24] - re-suspend syringe contents before injection by vigorously rolling syringe between palms[24] - if cold diluent reconstitution is used to extend stability, minimize exposure to RT; ensure proper refrigeration of diluent, reconstituted vial and final product[25,26]
	cold diluent reconstitution: 4 mL SWI at 2-8°C[25,26]	25 mg/mL[24]	12 h F[2,25,26]		22 h F[25,26]	

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
azaCITIDine 100 mg (Dr. Reddy's) (RT) no preservative[27]	4 mL SWI[27] shake vigorously[27]	25 mg/mL[27]	use within 45 min RT or 8 h F[27]	SC syringe[27]	45 min RT (including preparation time) or 8 h F[27] refrigerate syringe immediately after preparation if not to be used within 45 min of reconstitution[27] **Refrigerated syringes**[27]: • allow up to 30 min prior to administration to reach temperature of ~20-25°C • discard syringe if time elapsed at RT is greater than 30 min	- do not filter[27] - discard if contains large particles[27] - re-suspend syringe contents before injection by vigorously rolling syringe between palms[27]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
azaCITIDine 100 mg (Hikma) (RT) no preservative[28]	4 mL SWI[28] shake vigorously[28]	25 mg/mL[28]	use within 45 min RT or 8 h F[28]	SC syringe[28]	45 min RT (including preparation time) or 8 h F[28] refrigerate syringe immediately after preparation if not to be used within 45 min of reconstitution[28] **Refrigerated syringes**[28]: • allow up to 30 min prior to administration to reach temperature of ~20-25°C • discard syringe if time elapsed at RT is greater than 30 min	- do not filter[28] - discard if contains large particles[28] - re-suspend syringe contents before injection by vigorously rolling syringe between palms[28]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
BCG (*Tice* strain) **(OncoTICE®)** **intravesical** 50 mg (1 to 8 x 10^8 CFU) (Merck Canada) (F)(PFL) no preservative[29]	1 mL preservative-free NS[29] allow to stand for a few min; gently swirl to suspend[29] do NOT shake[29] record time of reconstitution	1 to 8×10^8 CFU/vial[29]	2 h F[29] **(PFL)[29]	transfer contents from vial to 50 mL syringe, rinse vial with 1 mL NS and transfer rinse solution to the 50 mL syringe, then qs up to 45 mL with NS[29] if a CSTD is used: transfer contents from vial to 50 mL syringe and qs up to 45 mL with NS; do NOT rinse vial[29]	use within 2 h F of reconstitution[29,30] **(PFL)[29]	- auxiliary info: biohazard[30] - do NOT filter[29] - do NOT shake[29]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
BCG (*Russian* strain) **(VERITY-BCG®)** **intravesical** 40 mg (1 to 8 x 10^8 CFU) (Verity) (F)(PFL) no preservative[31]	1 mL preservative-free NS[31] allow to stand for a few min; gently swirl to suspend[31] do NOT shake[31] record time of reconstitution	1 to 8×10^8 CFU/vial[31]	2 h F[31] **(PFL)[31]	transfer contents from 1st vial to 50 mL syringe, rinse vial with 1 mL NS and transfer rinse solution to the 50 mL syringe; then, repeat steps for 2nd vial and qs up to 45 mL with NS[31]	use within 2 h F of reconstitution[30,31] **(PFL)[31]	- auxiliary info: biohazard[30] - TWO vials must be used to achieve the recommended full dose[31] - do NOT shake[31]
Belantamab mafodotin 30 mg/1.5 mL (GSK) (frozen)(PFL) do not shake no preservative[32] (SAP)	n/a	20 mg/mL[32]	thaw up to 4 h RT, F before use[32] once thawed: **unpunctured** vial: 10 d F[32] once thawed: **punctured** vial: discard unused portion[30,32] **(PFL)[32] do NOT shake[32]	0.2-2 mg/mL NS[32] 250 mL* NS[32]	8 h RT[32]	- supplied as frozen liquid[32] - recommended freezer temp[32] is (-50°C to -15°C) - thawed drug cannot be refrozen[32]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Belantamab mafodotin 100 mg (GSK) (F)(PFL) no preservative[33] (SAP)	allow vial to stand at RT for 10 min before reconstitution[34] 2 mL SWI[33] swirl gently to mix; do NOT shake[34]	50 mg/mL[33]	use immediately after reconstitution[33] discard unused portion[33]	0.2-2 mg/mL NS[33] 250 mL* NS[33] mix by gentle inversion; do NOT shake[34]	complete administration within 8 h RT[33]	- discard if particulate matter is present[33]
Belinostat 500 mg (Spectrum) (RT) no preservative[35] (SAP)	9 mL SWI[35]	50 mg/mL[35]	12 h RT[35]	250 mL NS[35]	complete administration within 36 h RT[35]	- administer with 0.2 micron in-line filter[35]
Bendamustine 25 mg 100 mg (Natco) (RT)(PFL) no preservative[36]	25 mg: 5 mL SWI[36] 100 mg: 20 mL SWI[36] shake well; dissolves completely in 5 min[36]	5 mg/mL[36]	30 min[36]	0.2-0.6 mg/mL **NS**, D2.5-½NS[36] 100-500 mL†	complete administration within 24 h F, 3 h RT[36]	

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Bendamustine 25 mg 100 mg (Teva) (RT,F)(PFL) no preservative[37]	25 mg: 5 mL SWI[37] 100 mg: 20 mL SW[37] shake well; dissolves completely in 5 min[37]	5 mg/mL[37]	30 min[37]	0.2-0.6 mg/mL **NS**, D2.5-½NS[37] 100-500 mL†	complete administration within 24 h F, 3 h RT[38]	
Bevacizumab (AVASTIN®) 100 mg/4 mL 400 mg/16 mL (Roche) (F)(PFL) do not shake no preservative[39]	N/A	25 mg/mL[39]	discard unused portion[39]	1.4-16.5 mg/mL NS only[39] 100-250 mL†	48 h **F**, RT[39]	- do NOT shake[39]
Bevacizumab (MVASI®) 100 mg/4 mL 400 mg/16 mL (Amgen) (F)(PFL) do not shake no preservative[40]	N/A	25 mg/mL[40]	discard unused portion[40]	1.4-16.5 mg/mL NS only[40] 100-250 mL†	48 h **F**, RT[40]	- do NOT shake[40]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Bevacizumab (ZIRABEV®) 100 mg/4 mL 400 mg/16 mL (Pfizer) (F)(PFL) do not shake no preservative[41]	N/A	25 mg/mL[41]	discard unused portion[41]	1.4-16.5 mg/mL NS only[41] 100-250 mL†	10 d F, 48 h RT[2,41]	- do NOT shake[41]
Bleomycin 15 units (NB: dose in units only) (Fresenius Kabi) (F)(PFL) no preservative[42]	6 mL* NS[42]	2.5 units/mL	12 h F[2,42]	50 mL* NS[42]	24 h RT[42]	
Bleomycin 15 units (NB: dose in units only) (Pfizer/Hospira) (F)(PFL) no preservative[43]	6 mL* **NS,** SWI[43]	2.5 units/mL	12 h **F**, RT[2,43]	50 mL* NS[43]	4 h RT[2,30,43]	

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Blinatumomab 38.5 mcg (Amgen) (F)(PFL) do not shake no preservative[44]	3 mL SWI[44] do NOT use supplied IV solution stabilizer to reconstitute vials[44] direct diluent against side of vial during reconstitution[44] gently swirl to avoid excess foaming[44]	12.5 mcg/mL[44]	12 h F[2,45], 4 h RT[45]	250 mL NS[44] add supplied IV solution stabilizer to NS bag and gently mix to avoid foaming[44] add reconstituted drug to bag **following** addition of IV solution stabilizer[44]	complete administration within 10 d F, 96 h RT[45]	- use non-DEHP bag and IV administration set[44] - administer with 0.2 micron in-line filter[44] - prime lines with blinatumomab solution; do NOT use NS
Bortezomib **<u>SC injection</u>** 3.5 mg (Actavis) (RT)(PFL) no preservative[46]	1.4 mL NS[46]	2.5 mg/mL[46]	12 h **F**, RT[2,47]	SC syringe[46]	10 d F, 4 d RT[2,47]	- auxiliary info: WARNING: SUBCUTANEOUS use only. Fatal if given by other routes.

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Bortezomib 3.5 mg (Actavis) (RT)(PFL) no preservative[46]	3.5 mL NS[46]	1 mg/mL[46]	12 h **F**, RT[2,47]	IV syringe[46]	10 d F, 4 d RT[2,47]	- auxiliary info: WARNING: INTRAVENOUS use only. Fatal if given by other routes.
Bortezomib **SC injection** 3.5 mg (Apotex) (RT)(PFL) no preservative[48]	1.4 mL NS[48]	2.5 mg/mL[48]	12 h **F**, RT[2,49]	SC syringe[48]	10 d F, 4 d RT[2,49]	- auxiliary info: WARNING: SUBCUTANEOUS use only. Fatal if given by other routes.
Bortezomib 3.5 mg (Apotex) (RT)(PFL) no preservative[48]	3.5 mL NS[48]	1 mg/mL[48]	12 h **F**, RT[2,49]	IV syringe[48]	10 d F, 4 d RT[2,49]	- auxiliary info: WARNING: INTRAVENOUS use only. Fatal if given by other routes.

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Bortezomib **SC injection** 3.5 mg (Janssen) (RT)(PFL) no preservative[50]	1.4 mL NS[50]	2.5 mg/mL[50]	12 h **F**, RT[2,47]	SC syringe[50]	10 d F, 4 d RT[2,47]	- auxiliary info: WARNING: SUBCUTANEOUS use only. Fatal if given by other routes.
Bortezomib 3.5 mg (Janssen) (RT)(PFL) no preservative[50]	3.5 mL NS[50]	1 mg/mL[50]	12 h **F**, RT[2,47]	IV syringe[50]	10 d F, 4 d RT[2,47]	- auxiliary info: WARNING: INTRAVENOUS use only. Fatal if given by other routes.
Bortezomib **SC injection** 2.5 mg 3.5 mg (Juno/MDA) (RT)(PFL) no preservative[51]	2.5 mg: 1 mL NS[51] 3.5 mg: 1.4 mL NS[51]	2.5 mg/mL[51]	12 h **F**, RT[2,52]	SC syringe[51]	10 d F, 4 d RT[2,52]	- auxiliary info: WARNING: SUBCUTANEOUS use only. Fatal if given by other routes.

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Bortezomib 1 mg 2.5 mg 3.5 mg (Juno/MDA) (RT)(PFL) no preservative[51]	1 mg: 1 mL NS[51] 2.5 mg: 2.5 mL NS[51] 3.5 mg: 3.5 mL NS[51]	1 mg/mL[51]	12 h **F**, RT[2,52]	IV syringe[51]	10 d F, 4 d RT[2,52]	- auxiliary info: WARNING: INTRAVENOUS use only. Fatal if given by other routes.
Bortezomib **SC injection** 3.5 mg (Marcan) (RT)(PFL) no preservative[53]	1.4 mL NS[53]	2.5 mg/mL[53]	12 h F, RT[2,54,55]	SC syringe[53]	10 d F, 2 d RT[2,54,55]	- auxiliary info: WARNING: SUBCUTANEOUS use only. Fatal if given by other routes.
Bortezomib 3.5 mg (Marcan) (RT)(PFL) no preservative[53]	3.5 mL NS[53]	1 mg/mL[53]	12 h F, RT[2,54,55]	IV syringe[53]	10 d F, 2 d RT[2,54,55]	- auxiliary info: WARNING: INTRAVENOUS use only. Fatal if given by other routes.

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Bortezomib **SC injection** 3.5 mg (PMS) (RT)(PFL) no preservative[56]	1.4 mL NS[56]	2.5 mg/mL[56]	8 h RT[56]	SC syringe[56]	8 h RT[56]	- auxiliary info: WARNING: SUBCUTANEOUS use only. Fatal if given by other routes.
Bortezomib 3.5 mg (PMS) (RT)(PFL) no preservative[56]	3.5 mL NS[56]	1 mg/mL[56]	8 h RT[56]	IV syringe[56]	8 h RT[56]	- auxiliary info: WARNING: INTRAVENOUS use only. Fatal if given by other routes.
Bortezomib **SC injection** 1 mg 2.5 mg 3.5 mg (Taro) (RT)(PFL) no preservative[57]	1 mg: 0.4 mL NS[57] 2.5 mg: 1 mL NS[57] 3.5 mg: 1.4 mL NS[57]	2.5 mg/mL[57]	8 h RT[57]	SC syringe[57]	8 h RT[57]	- auxiliary info: WARNING: SUBCUTANEOUS use only. Fatal if given by other routes.

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Bortezomib 1 mg 2.5 mg 3.5 mg (Taro) (RT)(PFL) no preservative[57]	1 mg: 1 mL NS[57] 2.5 mg: 2.5 mL NS[57] 3.5 mg: 3.5 mL NS[57]	1 mg/mL[57]	8 h RT[57]	IV syringe[57]	8 h RT[57]	- auxiliary info: WARNING: INTRAVENOUS use only. Fatal if given by other routes.
Bortezomib **SC injection** 3.5 mg (Teva) (RT)(PFL) no preservative[58]	1.4 mL NS[58]	2.5 mg/mL[58]	12 h **F**, RT[2,47]	SC syringe[58]	10 d F, 4 d RT[2,47]	- auxiliary info: WARNING: SUBCUTANEOUS use only. Fatal if given by other routes.
Bortezomib 3.5 mg (Teva) (RT)(PFL) no preservative[58]	3.5 mL NS[58]	1 mg/mL[58]	12 h **F**, RT[2,47]	IV syringe[58]	10 d F, 4 d RT[2,47]	- auxiliary info: WARNING: INTRAVENOUS use only. Fatal if given by other routes.

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Brentuximab vedotin 50 mg (Seagen) (F)(PFL) no preservative[59]	10.5 mL SWI[59] direct diluent against side of vial during reconstitution[59] do NOT shake[59]	5 mg/mL[59]	12 h F[2,59]	0.4-1.8 mg/mL **NS**, D5W, Lactated Ringer's[59] 50-100 mL† gently invert to mix[59]	24 h F[2,59]	- solution should be colorless, clear to slightly opalescent, and free of visible particulates[59]
Busulfan 60 mg/10 mL (PMS) (F) no preservative[60]	N/A	6 mg/mL[60]	discard unused portion[30,60]	dilute to volume 10 times drug volume to achieve final concentration of ~0.5 mg/mL **NS**, D5W[60] 250-1000 mL†	complete administration within 12 h F, 8 h RT[60]	- contains DMA*** - always add busulfan to diluent to mix; do not add diluent to busulfan[60]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Busulfan 60 mg/10 mL (SteriMax) (F) no preservative[61]	N/A	6 mg/mL[61]	discard unused portion[23,61]	dilute to volume 10 times drug volume to achieve final concentration of ~0.5 mg/mL **NS**, D5W[61] 250-1000 mL†	in **NS**: complete administration within 12 h F, 8 h RT[61] in **D5W**: complete administration within 8 h RT[61]	- contains DMA*** - always add busulfan to diluent to mix; do not add diluent to busulfan[61]
Cabazitaxel 60 mg/1.5 mL (Dr. Reddy's) (RT) no preservative[62]	supplied diluent: withdraw entire contents of diluent vial and inject into the concentrate vial[62] slowly direct diluent against inside of vial to limit foaming[62] mix by repeated inversions for 45 sec[62] do NOT shake[62] let sit for 5 min[62]	10 mg/mL[62]	1 h RT[62]	0.10-0.26 mg/mL **NS**, D5W[62] 100-250 mL†	complete administration within 48 h F**,** 8 h RT[62]	- use non-DEHP bag and tubing[62] - administer with 0.2 micron in-line filter[62] - concentrate and diluent vials contain overfill[62] - diluent contains 13% (w/w) ethanol in water[62] - discard if crystallization occurs[62]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Cabazitaxel 45 mg/4.5 mL 60 mg/6 mL (Sandoz) (RT) preservative[63]	N/A	10 mg/mL[63]	10 d **F**, RT[63]	0.10-0.26 mg/mL **NS**, D5W[63] 100-250 mL†	complete administration within 48 h F, 8 h RT[63]	- use non-DEHP bag and tubing[63] - administer with 0.2 micron in-line filter[63] - vials contain overfill[63]
Cabazitaxel 60 mg/1.5 mL (sanofi-aventis) (RT) no preservative[64]	supplied diluent: withdraw entire contents of diluent vial and inject into the concentrate vial[64] slowly direct diluent against inside of vial to limit foaming[64] mix by repeated inversions for 45 sec[64] do NOT shake[64] let sit for 5 min[64]	10 mg/mL[64]	1 h RT[64]	0.10-0.26 mg/mL **NS**, D5W[64] 100-250 mL†	complete administration within 48 h F**,** 8 h RT[64]	- use non-DEHP bag and tubing[64] - administer with 0.2 micron in-line filter[64] - concentrate and diluent vials contain overfill[64] - diluent contains 13% (w/w) ethanol in water[64] - discard if crystallization occurs[64]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
CARBOplatin 50 mg/5 mL 150 mg/15 mL 450 mg/45 mL 600 mg/60 mL (Accord) (RT)(PFL) no preservative[65]	N/A	10 mg/mL[65]	discard unused portion[65]	0.5-10 mg/mL **NS**, D5W[65] 50-250 mL†	24 h F, 8 h RT[65]	- do NOT use aluminum-containing needle, syringe, or tubing[65]
CARBOplatin 50 mg/5 mL 150 mg/15 mL 450 mg/45 mL 600 mg/60 mL (Omega) (RT)(PFL) no preservative[66]	N/A	10 mg/mL[66]	discard unused portion[66]	0.3-10 mg/mL **NS**, D5W[66] 50-250 mL†	48 h F[66], 24 h RT[67]	- do NOT use aluminum-containing needle, syringe or tubing[66]
CARBOplatin 50 mg/5 mL 150 mg/15 mL 450 mg/45 mL 600 mg/60 mL (Pfizer/Hospira) (RT)(PFL) no preservative[68]	N/A	10 mg/mL[68]	discard unused portion[68]	0.3-10 mg/mL **NS**, D5W[68] 50-250 mL†	48 h F[68]	- do NOT use aluminum-containing needle, syringe, or tubing[68]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
CARBOplatin 50 mg/5 mL 150 mg/15 mL 450 mg/45 mL (Teva) (RT)(PFL) no preservative[69]	N/A	10 mg/mL[69]	discard unused portion RT[69]	0.5-10 mg/mL[70] **NS**, D5W[69,71,72] 50-250 mL†	8 h F[73], RT[69]	- do NOT use aluminum-containing needle, syringe, or tubing[69]
Carfilzomib 10 mg 30 mg 60 mg (Amgen) (F)(PFL) no preservative[74]	10 mg: 5 mL SWI[74] 30 mg: 15 mL SWI[74] 60 mg: 29 mL SWI[74] direct diluent against side of vial during reconstitution[74] swirl gently; do NOT shake[74] if foaming occurs, allow to settle until clear (~5 min)[74]	2 mg/mL[74]	12 h **F**, 4 h RT[2,74]	50-100 mL* **D5W** only[74] do NOT dilute in NS[74]	24 h **F**, 4 h RT[2,74]	- if a CSTD is not used in compounding, a 21 gauge (or larger gauge) needle is recommended to prevent coring of the vial stopper[75-77] - do not use NS for reconstitution or dilution[74] - discard if contains particulates[74]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Carmustine 100 mg (SteriMax) (F) no preservative[78]	3mL supplied diluent[78] bring drug and diluent vials to RT prior to mixing[78] completely dissolve drug in diluent, then add 27 mL SWI[78]	3.3 mg/mL in ethanol 10%[78]	48 h F[78] precipitates can be re-dissolved by warming the vial to RT with gentle shaking[78]	500 mL NS, D5W[78] in glass or polypropylene containers ONLY[78]	8 h RT[78] or 48 h F plus an additional 6 h RT[78] **(PFL)[78]	- supplied diluent is dehydrated alcohol[78] - do not use vial if oily film is present[78] - final product should be gently shaken for ~10 sec to remix bag contents prior to administration[78] - administer with PVC-free infusion set[78] - protect from light for administration[78]
Cemiplimab 250 mg/5 mL 350 mg/7 mL (sanofi) (F)(PFL) do not shake no preservative[79]	N/A	50 mg/mL[79]	discard unused portion[30,79]	1-20 mg/mL **NS**, D5W[79] 50 mL† mix by gentle inversion	complete administration within 24 h F, 8 h RT[79]	- administer with 0.2 micron filter[79] - solution may contain white particulates which do not affect product quality[79]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Cetuximab 100 mg/50 mL 200 mg/100 mL (Imclone/Lilly) (F) do not shake no preservative[80]	N/A	2 mg/mL[80]	12 h F, 8 h RT[80]	syringe[80] evacuated container or bag[80]	12 h F, 8 h RT[80]	- administer with 0.2 micron filter[80] - solution may contain white particulates which do not affect product quality[80]
CISplatin 10 mg/10 mL 50 mg/50 mL 100 mg/100mL (Accord) (RT)(PFL) no preservative[81]	N/A	1 mg/mL[81]	discard unused portion[30]	NS[81] 100-500 mL† or 2 L D5-½NS or D5-⅓NS containing 37.5 g of mannitol[81]	24 h RT[81]	- do NOT use aluminum-containing needle, syringe or tubing[81] - suggested dose limits relate to the physical limitations of the bag size and added drug volume; it is not a concentration-dependent property of the drug - for ULY0 D-PACE protocol, see entry for DPACE (3-in-1 solution containing etoposide, CISplatin, cyclophosphamide)

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
CISplatin 50 mg/50 mL 100 mg/100mL (Pfizer/Hospira) (RT)(PFL) no preservative[82]	N/A	1 mg/mL[82]	discard unused portion[30]	NS[82] 100-500 mL† or 2 L D5-½NS or D5-⅓NS containing 37.5 g of mannitol[82]	24 h RT[82]	- do NOT use aluminum-containing needle, syringe or tubing[82] - suggested dose limits relate to the physical limitations of the bag size and added drug volume; it is not a concentration-dependent property of the drug - for ULY0 D-PACE protocol, see entry for DPACE (3-in-1 solution containing etoposide, CISplatin, cyclophosphamide)

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
CISplatin 10 mg/10 mL 50 mg/50 mL 100 mg/100mL (Sandoz) (RT)(PFL) no preservative[83]	N/A	1 mg/mL[83]	12 h RT[2,84]	NS[83] 100-500 mL† or 2 L D5-½NS or D5-⅓NS containing 37.5 g of mannitol[83]	24 h RT[84]	- do NOT use aluminum-containing needle, syringe or tubing[83] - suggested dose limits relate to the physical limitations of the bag size and added drug volume; it is not a concentration-dependent property of the drug - for ULY0 D-PACE protocol, see entry for DPACE (3-in-1 solution containing etoposide, CISplatin, cyclophosphamide)

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
CISplatin 10 mg/10 mL 50 mg/50 mL 100 mg/100mL (Teva) (RT)(PFL) no preservative[85]	N/A	1 mg/mL[85]	discard unused portion[23]	NS[85] 100-500 mL† or 2 L D5-½NS or D5-⅓NS containing 37.5 g of mannitol[85]	24 h RT[85]	- do NOT use aluminum-containing needle, syringe or tubing[85] - suggested dose limits relate to the physical limitations of the bag size and added drug volume; it is not a concentration-dependent property of the drug - for ULY0 D-PACE protocol, see entry for DPACE (3-in-1 solution containing etoposide, CISplatin, cyclophosphamide)

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Cladribine 10 mg/10 mL (Fresenius Kabi) (F)(PFL) no preservative[86]	N/A	1 mg/mL[86]	discard unused potion[86]	SC syringe[87]	48 h F, discard end of day RT[30,88,89]	
				500 mL **NS only**[86] do NOT use D5W[86]	24 h **RT**[86]	
				Cassette: qs to 100 mL with **bacteriostatic NS only** via SIMS DELTEC INC. MEDICATION CASSETTES®[86] filter drug and diluent through 0.22 micron filter as each solution is being introduced into the cassette[86]	at least 7 days[86]	

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Cladribine 10 mg/10 mL (GMP) (F)(PFL) no preservative[90]	N/A	1 mg/mL[90]	discard unused portion[30,90]	SC syringe[87]	48 h F, discard end of day RT[30,88,89]	
				500 mL NS only[90] do NOT use D5W[90]	24 h RT[90]	
				Cassette: qs to 100 mL with **bacteriostatic NS only** via SIMS DELTEC INC. MEDICATION CASSETTES®[90] filter drug and diluent through 0.22 micron filter as each solution is being introduced into the cassette[90]	at least 7 days[90]	

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Crisantaspase (recombinant asparaginase *Erwinia chrysanthemum*) 10 mg/0.5 mL (Jazz) (F)(PFL) do not shake preservative free[91]	N/A	20 mg/mL[91]	discard unused portion[91]	IM syringe[91] max volume: 2 mL if volume >2 mL, use multiple sites[91]	use within 4 h RT[91] (PFL NOT required for syringe)[91]	- discard if cloudy, discoloured, or contains particulates[91] - do NOT shake[91]
Cyclophosphamide 200 mg 500 mg 1000 mg 2000 mg (Baxter) (RT)(PFL) no preservative[92]	200 mg[92]: 10 mL NS 500 mg[92]: 25 mL NS 1000 mg[92]: 50 mL NS 2000 mg[92]: 100 mL NS	20 mg/mL[92]	12 h **F**, RT[2,92]	**NS**, D5W, D5NS[92] 100-250 mL† high dose in BMT: may need 500 mL*	36 h F, 24 h RT[93-95]	- suggested dose limits relate to the physical limitations of the bag size and added drug volume; it is not a concentration-dependent property of the drug - for ULY0 D-PACE protocol, see entry for DPACE (3-in-1 solution containing etoposide, CISplatin, cyclophosphamide)

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Cytarabine 1000 mg/10mL 2000 mg/20mL (Pfizer/Hospira) (RT)(PFL) no preservative[96]	N/A	100 mg/mL[96]	12 h RT[2,96]	0.1-37.5 mg/mL **NS,** D5W, SWI[96] 100 mL†	in NS: 4 d RT[2,96] other solutions: 72 h F, 24 h RT[96] **(PFL)[96]	
Cytarabine **IT injection** 1000 mg/10mL 2000 mg/20mL (Pfizer/Hospira) (RT)(PFL) no preservative[96]	N/A record time of puncture	100 mg/mL[96]	use within 4 h of initial puncture[2]	IT syringe qs to 6 mL with preservative free NS[97-99] diluents containing preservatives should **NOT** be used for intrathecal administration[100]	use within 4 h of initial puncture[2] **(PFL)[96]	- auxiliary info[2]: IT - label to include route in full (i.e., INTRATHECAL injection) attached to both syringe and outer ziplock bag[99]
Cytarabine **SC injection** 1000 mg/10mL 2000 mg/20mL (Pfizer/Hospira) (RT)(PFL) no preservative[96]	N/A	100 mg/mL[96]	12 h RT[2,96]	SC syringe	10 d F, 4 d RT[2,101-103] **(PFL)[96]	

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Cytarabine 1000 mg/10mL 2000 mg/20mL (PMS) (RT)(PFL) no preservative[104]	N/A	100 mg/mL[104]	discard unused portion[30,104]	0.1-37.5 mg/mL **NS,** D5W, SWI[104] 100 mL†	10 d F, 48 h RT[104] **(PFL)	
Cytarabine **IT injection** 1000 mg/10mL 2000 mg/20mL (PMS) (RT)(PFL) no preservative[104]	N/A record time of puncture	100 mg/mL[104]	use within 4 h of initial puncture[30]	IT syringe qs to 6 mL with preservative free NS[97,98] diluents containing preservatives should **NOT** be used for intrathecal administration[100]	use within 4 h of initial puncture[30] **(PFL)	- auxiliary info: IT[30] - label to include route in full (i.e., INTRATHECAL injection) attached to both syringe and outer ziplock bag[99]
Cytarabine **SC injection** 1000 mg/10mL 2000 mg/20mL (PMS) (RT)(PFL) no preservative[104]	N/A	100 mg/mL[104]	discard unused portion[30,104]	SC syringe	10 d F, 48 h RT[104] **(PFL)	

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Cytarabine 2000 mg/20mL (SteriMax) (RT)(PFL) no preservative[105]	N/A	100 mg/mL[105]	12 h RT[2,105]	0.1-37.5 mg/mL **NS,** D5W, SWI, LR[105] 100 mL*	in NS: 4 d RT[2,105] other solutions: 72 h F, 24 h RT[105] **(PFL)[105]	
Cytarabine **IT injection** 2000 mg/20mL (SteriMax) (RT)(PFL) no preservative[105]	N/A record time of puncture	100 mg/mL[105]	use within 4 h of initial puncture[2]	IT syringe qs to 6 mL with preservative free NS[97-99] diluents containing preservatives should **NOT** be used for intrathecal administration[100]	use within 4 h of initial puncture[2] **(PFL)[105]	- auxiliary info: IT[2] - label to include route in full (i.e., INTRATHECAL injection) attached to both syringe and outer ziplock bag[99]
Cytarabine **SC injection** 2000 mg/20mL (SteriMax) (RT)(PFL) no preservative[105]	N/A	100 mg/mL[105]	12 h RT[2,105]	SC syringe	10 d F, 4 d RT[2,101-103] **(PFL)[105]	

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Dacarbazine 600 mg (Pfizer) (F)(PFL) no preservative[106]	59.1 mL SWI[106]	10 mg/mL[106]	12 h F, 8 h RT[2,106]	0.19-3.0 mg/mL **NS**, D5W[106] 500-1000 mL†	24 h F[106] **(PFL)[107]	- protect container from light during administration[107]
DACTINomycin 0.5 mg (GMD Pharma for Recordati) (RT)(PFL) no preservative[108] (SAP)	1.1 mL SWI (preservative-free)[108] do **NOT** use SWI with preservative (may form precipitate)[108]	0.5 mg/mL (500 mcg/mL)[108]	discard unused portion[109]	syringe[108] 10 mcg/mL or greater[108] **NS**, D5W[108,110]	use within 4 h of initial vial puncture[109]	- drug loss reported with some cellulose ester membrane in- line filters[108]
Daratumumab 100 mg/5mL 400 mg/20mL (Janssen) (F)(PFL) do not shake no preservative[111]	N/A	20 mg/mL[111]	discard unused portion[111]	500-1000 mL NS dilute to final volume by withdrawing volume from bag equal to volume of drug to be added[111] mix by gentle inversion[111]	24 h **F,** followed by 15 h infusion (total 39 h)[111] allow bag to come to RT, then use immediately[111] **(PFL)	- administer with 0.2 micron in-line filter[111] - discard if visible particles are observed[111] - complete infusion within 15 h[111]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Daratumumab <u>subcutaneous</u> (DARZALEX SC®) 1800 mg/15 mL (Janssen) (F)(PFL) do not shake no preservative[112]	N/A	120 mg/mL[112] allow vial to come to RT prior to use[112]	discard unused portion[2,112]	SC syringe[112]	24 h F, plus an additional 12 h RT[112] bring to RT prior to use[112]	- contains hyaluronidase[112] - formulations are NOT interchangeable[112] - discard if opaque particles or discolouration are present[112] - unpunctured vial may be stored up to 24 h at RT[112]
DAUNOrubicin 20 mg (Erfa) (RT)(PFL) no preservative[113]	4 mL SWI[113]	5 mg/mL[113]	12 h **F**, RT[2,113] **(PFL)[113]	100-250 mL **NS**, D5W[113]	48 h F, 24 h RT[114] **(PFL)[113]	

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Daunorubicin-cytarabine liposome 44 mg-100 mg (Jazz) (F)(PFL) no preservative[115]	19 mL **SWI**[115] allow vial to come to RT for 30 min prior to use[115] swirl gently for 5 min, inverting the vial every 30 sec; do NOT shake[115] allow vial to rest for 15 min after reconstitution[115] gently invert each vial 5 times prior to withdrawing concentrate for dilution[115] record time of reconstitution	2.2 mg/mL daunorubicin-5 mg/mL cytarabine[115]	4 h **F**[115] max *combined* storage time for reconstituted vial and diluted product is 4 h **F** (NOT 4 h **F** each)[115]	500 mL **NS**, D5W[115] mix by gentle inversion[115]	4h **F**[115] max *combined* storage time for reconstituted vial and diluted product is 4 h **F** (NOT 4 h **F** each)[115]	- reconstituted product is an opaque, purple, homogenous dispersion[115] - before administration, final product should be gently inverted to remix solution after refrigeration[115]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Degarelix 80 mg 120 mg (Ferring) (RT) do not shake[116] no preservative[117]	80 mg: 4.2 mL SWI (supplied diluent)[116]	20 mg/mL[116]	2 h RT[116]	SC syringe[116]	2 h RT[116]	
	120 mg: 3 mL SWI (supplied diluent)[116]	40 mg/mL[116]				
	swirl gently; avoid shaking to prevent foam formation[116] reconstitution may take up to 15 min[116]					

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Denosumab (XGEVA®) 120 mg/1.7 mL (Amgen) (F)(PFL) do not shake no preservative[118]	N/A	71 mg/mL[118]	discard unused portion[109,118]	SC syringe[118]	use within 4 h F, RT of initial puncture[109] bring to RT 15-30 min prior to use[118]	- not interchangeable with PROLIA[118] - do not use if solution is cloudy; trace amounts of translucent to white proteinaceous particles are acceptable[118] - avoid vigorous shaking[118]
Dexrazoxane 250 mg 500 mg (Hikma USA) (RT) no preservative[119,120]	250 mg: 25 mL SWI[120] 500 mg: 50 mL SWI[120]	10 mg/mL[120]	3 h F, 30 min RT[120]	MUST BE FURTHER DILUTED with Lactated Ringers to 1.3-3.0 mg/mL[120]	4 h F, 1 h RT[120]	
Dexrazoxane 250 mg 500 mg (Pfizer) (RT) no preservative[121]	250 mg: 25 mL SWI[121] 500 mg: 50 mL SWI[121]	10 mg/mL[121]	3 h F, 30 min RT[121]	MUST BE FURTHER DILUTED with Lactated Ringers to 1.3-3.0 mg/mL[121]	4 h F, 1 h RT[121]	

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Dinutuximab 17.5 mg/5 mL (Unither/United Therapies) (F)(PFL) do not shake no preservative[122]	N/A	3.5 mg/mL[122]	discard unused portion[30]	100 mL NS[122] mix by gentle inversion[122]	initiate infusion within 4 h of dilution; refrigerate bag if not hung immediately[122] complete administration within 24 h of dilution[122]	- do NOT shake[122]

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
DOCEtaxel 20 mg/2 mL 80 mg/8 mL 160 mg/16 mL (Pfizer/Hospira) (**F**, RT)(PFL) preservative[123]	N/A	10 mg/mL[123]	20mg: discard unused portion[2,123] 80 mg or 160 mg: 28 d F[2,123] **(PFL)[123] (max number of punctures: up to 3 doses can be removed when a filtered venting needle [e.g., Chemo-Vent®] is also inserted, i.e., 6 punctures total)[124]	0.3-0.74 mg/mL **NS,** D5W[123] 100-500 mL†	10 d F, 4 d RT[2,125] **(PFL)[125] during F storage	- use non-DEHP bag and IV administration set[123]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
DOCEtaxel **intravesical** 20 mg/2 mL 80 mg/8 mL 160 mg/16 mL (Pfizer/Hospira) (**F**, RT)(PFL) preservative[123]	N/A	10 mg/mL[123]	20 mg: discard unused portion[2,123] 80 mg or 160 mg: 28 d F[2,123] **(PFL)[123] (max number of punctures: up to 3 doses can be removed when a filtered venting needle [e.g., Chemo-Vent®] is also inserted, i.e., 6 punctures total)[124]	syringe dilute with NS to final volume of 45 mL[126,127]	up to 0.9 mg/mL: 10 d F, 4 d RT[2,125] **(PFL)[125] during F storage	
DOCEtaxel 20 mg/2 mL 80 mg/8 mL 160 mg/16 mL (Sandoz) (F,RT)(PFL) preservative[128]	N/A	10 mg/mL[128]	28 d **F**, RT[2,129]	0.3-0.74 mg/mL **NS**, D5W[128] 100-500 mL†	24 h F, 4 h RT[2,130]	- use non-DEHP bag and IV administration set[128]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
DOCEtaxel **intravesical** 20 mg/2 mL 80 mg/8 mL 160 mg/16 mL (Sandoz) (F,RT)(PFL) preservative[128]	N/A	10 mg/mL[128]	28 d **F**, RT[2,129]	syringe dilute with NS to final volume of 45 mL[126,127]	up to 0.9 mg/mL[131,132]: use immediately after preparation to prevent particle formation[2,130]	- particle formation occurs earlier with higher temperature and higher concentrations[130]
DOXOrubicin 10 mg/5 mL 20 mg/10 mL 50 mg/25 mL 200 mg/100 mL (Accord) (F)(PFL) no preservative[133]	N/A	2 mg/mL[133]	8 h[133]	syringe[133]	24 h **F**, RT from initial vial puncture[133]	- for LYEPOCHR protocol, see entry for EPOCHR (3-in-1 solution containing either etoposide or etoposide phosphate AND DOXOrubicin and vinCRIStine)
				0.01–2 mg/mL NS[134,135] 1000 mL[136-138]	24 h RT[134,135]	

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
DOXOrubicin 10 mg/5 mL 20 mg/10 mL 50 mg/25 mL 200 mg/100 mL (Teva) (F)(PFL) no preservative[139]	N/A	2 mg/mL[139]	8 h[139]	syringe[139]	48 h F, 24 h RT[139] from initial vial puncture	- for LYEPOCHR protocol, see entry for EPOCHR (3-in-1 solution containing either etoposide or etoposide phosphate AND DOXOrubicin and vinCRIStine)
				0.01–2 mg/mL NS[134,135] 1000 mL[136-138]	24 h RT[134,135]	
DOXOrubicin 10 mg/5 mL 50 mg/25 mL 200 mg/100 mL (Pfizer) (F) no preservative[140]	N/A	2 mg/mL[140]	discard unused portion[109,140]	syringe[140]	48 h F, 24 h RT[140]	- for LYEPOCHR protocol, see entry for EPOCHR (3-in-1 solution containing either etoposide or etoposide phosphate AND DOXOrubicin and vinCRIStine)
				0.01–2 mg/mL NS[134,135] 1000 mL[136-138]	24 h RT[134,135]	

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
DOXOrubicin Pegylated Liposomal 20 mg/10 mL (Janssen) (F) no preservative[141]	N/A	2 mg/mL[141]	discard unused portion[141]	**D5W** only[141] <90 mg: 250 mL[141] ≥90 mg: 500mL[141]	24 h F[141]	- do not filter[141]
DOXOrubicin Pegylated Liposomal 20 mg/10 mL 50 mg/25 mL (Taro) (F) no preservative[142]	N/A	2 mg/mL[142]	discard unused portion[142]	**D5W** only[142] <90 mg: 250 mL[142] ≥90 mg: 500mL[142]	24 h F[142]	- do not filter[142]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
DPACE (ULY0D-PACE protocol) (RT) no preservative[2,138,143,144]	see brand specific entries for: cyclophosphamide as applicable	see brand specific entries for: CISplatin, cyclophosphamide, etoposide	see brand specific entries for: CISplatin, cyclophosphamide, etoposide	in 1000 mL NS[137,143,144]	≤0.2 mg/mL: 24 h RT[2,143,144]	- final product is a 3-in-1 solution containing etoposide, CISplatin, cyclophosphamide (see ULY0D-PACE protocol) - use non-DEHP bag and tubing only - administer with 0.2 micron in-line filter

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Durvalumab 120 mg/2.4 mL 500 mg/10 mL (AstraZeneca) (F)(PFL) do not shake no preservative[145]	N/A	50 mg/mL[145]	discard unused portion[145]	1-15 mg/mL **NS**, D5W[145] 100 mL† mix by gentle inversion[145]	10 d F, 12 h RT[2,145]	- do NOT shake[145] - administer with 0.2 micron in-line filter[145] - discard vial if solution is cloudy, discolored, or visible particles are present[145] - use filtered venting needle (e.g., Chemo-Vent®) in place of CSTD for compounding[146]
Elranatamab 44 mg/1.1 mL 76 mg/1.9 mL (Pfizer) (F)(PFL) do not shake no preservative[147]	N/A	40 mg/mL[147] allow vials to reach RT before using[147]	discard unused portion[147]	SC syringe[147]	use within 4 h **F**, RT[147]	- do not use if contains particulates[147]

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Elranatamab 76 mg/1.9 mL (Pfizer) (F)(PFL) no preservative[148] (SAP)	N/A	40 mg/mL[148] allow vials up to 15 min to reach RT before using[148]	discard unused portion[2,148]	SC syringe[148]	use immediately after preparation[2,148]	- supplied diluent to be used only for doses <8 mg[148] - solution colour may be colourless to yellow/brown[148] - unpunctured vials can be kept at RT up to 8 h before returning to F; discard if longer than 8 h RT[148] - solutions can be prepared in normal room light; avoid direct sunlight[148] - CSTD cannot be used during storage of prepared doses[148,149] - to **prepare** 76 mg dose ONLY: use filtered venting needle (e.g., Chemo-Vent®) in place of CSTD[150]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Enfortumab vedotin 20 mg 30 mg (Seagen) (F)(PFL) do not shake no preservative[151]	20 mg[151]: 2.3 mL SWI 30 mg[151]: 3.3 mL SWI slowly swirl until completely dissolved; do not shake[151] allow to settle until bubbles are gone (≥1 min)[151]	10 mg/mL[151]	12 h F[2,151]	0.3-4 mg/mL **NS**, D5W, Lactated Ringer's[151] 50 mL* mix by gentle inversion[151]	16 h F[151] **(PFL)[151]	- discard if visible particles are present or solution is discolored[151] - do not shake[151]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Epcoritamab (AbbVie) 4 mg/0.8 mL (F)(PFL) do not shake no preservative[152]	N/A bring vial to RT prior to use (<1 h)[152] gently swirl vial prior to use[152] do not invert, vortex, or shake[152]	5 mg/mL[152] **For Step-up Dose 1 (0.16 mg)**[152] To create **intermediate vial (0.8 mg/mL): using 4 mg vial**: transfer 0.8 mL drug solution into empty vial and add 4.2 mL NS; gently swirl for 30-45 sec	discard unused portion[152]	SC syringe[152] **For Step-up Dose 1 (0.16 mg)**[152] To create **dosing vial (0.16 mg/mL):** transfer 2.0 mL from intermediate vial into the dosing vial and add 8.0 mL NS; gently swirl for 30-45 sec withdraw 1.0 mL into syringe for administration[152] mix gently; do not invert, vortex, or shake[152]	24 h F, 12 h RT[152] (RT storage includes preparation) **(PFL)[152]	- **CAUTION:** two concentrations are available - **use 4 mg vial for step-up doses only**[152] - minimize exposure to daylight[152]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Epcoritamab (AbbVie) 4 mg/0.8 mL (F)(PFL) do not shake no preservative[152]	N/A bring vial to RT prior to use (<1 h)[152] gently swirl vial prior to use[152] do not invert, vortex, or shake[152]	5 mg/mL[152] For **Step-up Dose 2 (0.8 mg)**[152] To create **intermediate vial (0.8 mg/mL): using 4 mg vial**: transfer 0.8 mL drug solution into empty vial and add 4.2 mL NS; gently swirl for 30-45 sec	discard unused portion[152]	SC syringe[152] For **Step-up Dose 2 (0.8 mg)**[152] withdraw 1.0 mL from the intermediate vial into syringe for administration mix gently; do not invert, vortex, or shake[152]	24 h F, 12 h RT[152] (RT storage includes preparation) **(PFL)[152]	- **CAUTION:** two concentrations are available[152] - **use 4 mg vial for step-up doses only**[152] - minimize exposure to daylight[152]
Epcoritamab (AbbVie) 48 mg/0.8 mL (F)(PFL) do not shake no preservative[152]	N/A bring vial to RT prior to use (<1 h)[152] gently swirl vial prior to use[152] do not invert, vortex, or shake[152]	60 mg/mL[152]	discard unused portion[152]	SC syringe[152] do not invert, vortex, or shake[152]	24 h F, 12 h RT[152] (RT storage includes preparation) **(PFL)[152]	- **CAUTION:** two concentrations are available - **use 48 mg vial for full doses only**[152] - minimize exposure to daylight[152]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Epcoritamab (AbbVie) 4 mg/0.8 mL (F)(PFL) do not shake no preservative[153] (SAP)	N/A bring vial to RT prior to use[153] gently swirl vial prior to use[153]	5 mg/mL[153] **For Step-up Dose 1[153] (0.16 mg)** To create **intermediate vial (0.8 mg/mL): using 4 mg vial**: transfer 0.8 mL drug solution into empty vial and add 4.2 mL NS; gently swirl for 30-45 sec (at 45 degree angle)	discard unused portion[153]	SC syringe[153] **For Step-up Dose 1[153] (0.16 mg)** To create **dosing vial (0.16 mg/mL):** transfer 2.0 mL from intermediate vial into the dosing vial and add 8.0 mL NS; gently swirl for 30-45 sec (at 45 degree angle) withdraw 1.0 mL into syringe for administration	24 h[153]; to a maximum of 20 h F, 4 h RT[153] mix gently; do not invert, vortex, or shake[153]	- **CAUTION:** two concentrations are available[153] - **use 4 mg vial for step-up doses only**[153] - do not use if visible particles are observed[153] - do not use CSTD for preparation or administration[153]; use filtered venting needle (Chemo-Vent®) for preparation

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Epcoritamab (AbbVie) 4 mg/0.8 mL (F)(PFL) do not shake no preservative[153] (SAP)	N/A bring vial to RT prior to use[153] gently swirl vial prior to use[153]	5 mg/mL[153] For **Step-up Dose 2 (0.8 mg)**[153] To create **intermediate vial (0.8 mg/mL): using 4 mg vial**: transfer 0.8 mL drug solution into empty vial and add 4.2 mL NS; gently swirl for 30-45 sec (at 45 degree angle)	discard unused portion[153]	SC syringe[153] For **Step-up Dose 2 (0.8 mg)**[153] withdraw 1.0 mL from the intermediate vial into syringe for administration	24 h[153]; to a maximum of 20 h F, 4 h RT[153] mix gently; do not invert, vortex, or shake[153]	- **CAUTION:** two concentrations are available[153] - **use 4 mg vial for step-up doses only**[153] - do not use if visible particles are observed[153] - do not use CSTD for preparation or administration[153]; use filtered venting needle (Chemo-Vent®) for preparation

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Epcoritamab (AbbVie) 48 mg/0.8 mL (F)(PFL) do not shake no preservative[153] (SAP)	N/A bring vial to RT prior to use[153] gently swirl vial prior to use[153]	60 mg/mL[153]	discard unused portion[153]	SC syringe[153]	24 h[153]; to a maximum of 20 h F, 4 h RT[153] mix gently; do not invert, vortex, or shake[153]	- **CAUTION:** two concentrations are available[153] - **use 48 mg vial for full doses only**[153] - do not use if visible particles are observed[153] - do not use CSTD for preparation or administration[153]; use filtered venting needle (Chemo-Vent®) for preparation
Epirubicin 10 mg/5 mL 20 mg/10 mL 50 mg/25 mL 150 mg/75 mL 200 mg/100 mL (Teva/Novopharm) (F)(PFL) no preservative[154]	N/A	2 mg/mL[154]	8 h **F**, RT[154]	syringe[154]	48 h **F**, 24 h RT from initial vial puncture[154]	

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Epirubicin 10 mg/5 mL 50 mg/25 mL 200 mg/100 mL (Fresenius Kabi) (F)(PFL) no preservative[155]	N/A record time of puncture	2 mg/mL[155]	8 h[155]	syringe[155]	48 h **F**, 24 h RT from initial vial puncture[155]	
				100 mL***** **NS,** D5W	48 h **F**, RT[23,155]	
Epirubicin 10 mg/5 mL 50 mg/25 mL 200 mg/100 mL (Pfizer) (F)(PFL) no preservative[156]	N/A record time of puncture	2 mg/mL[156]	8 h[156]	syringe[156]	48 h **F**, 24 h RT from initial vial puncture[156]	
				100 mL* **NS,** D5W[71]	48 h **F**, RT[157]	

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
EPOCHR (LYEPOCHR protocol) (RT) no preservative[23,158-161]	see brand specific entries for: DOXOrubicin as applicable	see brand specific entries for: DOXOrubicin, etoposide, vinCRIStine	see brand specific entries for: DOXOrubicin, etoposide, vinCRIStine	etoposide dose ≤125 mg/24 h: in 500 mL NS etoposide dose >125 mg/24 h: in 1000 mL NS	etoposide concentration ≤0.25 mg/mL: complete administration within 72 h RT precipitation occurs at etoposide concentrations >0.25 mg/mL	- final product is a 3-in-1 solution containing **etoposide**, DOXOrubicin, and vinCRIStine (refer to LYEPOCHR protocol) - use non-DEHP bag and tubing only - administer with 0.2 micron in-line filter
EPOCHR with etoposide phosphate (LYEPOCHR protocol) (RT) no preservative[162,163]	see brand specific entries for: DOXOrubicin and etoposide phosphate as applicable	see brand specific entries for: DOXOrubicin, etoposide phosphate, vinCRIStine	see brand specific entries for: DOXOrubicin, etoposide phosphate, vinCRIStine	500 mL **NS**[164]	4 d RT, 5 d F[2,162]	- final product is a 3-in-1 solution containing **etoposide phosphate**, DOXOrubicin, and vinCRIStine (refer to LYEPOCHR protocol)

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
eriBULin 1 mg/2 mL (Eisai Limited) (RT)(PFL)[165] no preservative[23]	N/A	0.5 mg/mL[165]	discard unused portion[23,165]	IV syringe[165]	24 h **F**, 6 h RT[165]	- do not administer through dextrose containing lines[165] - vials contain dehydrated alcohol USP (5% v/v)[165]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Etoposide 100 mg/5 mL 200 mg/10 mL 500 mg/25 mL 1000 mg/50 mL (Teva) (RT)(PFL) no preservative[166]	N/A	20 mg/mL[166]	discard unused portion[166]	0.2-0.4 mg/mL NS[166] 100-1000 mL†	stability is concentration dependent **0.2-0.3 mg/mL:** 7 d F,[167] 2 d RT[167,168] **0.4-0.5 mg/mL**: 1 d F,[167] 1d RT[167] **0.6-9.0 mg/mL**: generally unstable **9.5 mg/mL:** 2 d F,[167] 1d RT[167] **10-12 mg/mL:** 7 d F,[167] 2 d RT[167,168]	- use non-DEHP bag and tubing only - administer with 0.2 micron in-line filter[169] - for LYEPOCHR protocol, see entry for EPOCHR (3-in-1 solution containing either etoposide or etoposide phosphate AND DOXOrubicin and vinCRIStine) - for ULY0 D-PACE protocol, see entry for DPACE (3-in-1 solution containing etoposide, CISplatin, cyclophosphamide)
				D5W[166]	4 h RT[166,170]	

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Etoposide phosphate (**ETOPOPHOS®**) 100 mg (Xediton/Cheplapharm) (F)(PFL) no preservative[171-173] (SAP)	5 mL NS, D5W, SWI, BWI[174]	20 mg/mL[174]	in NS, D5W, SWI: 12 h F, RT[2,174] in BWI: 7 d F, 48 h RT[174]	500 mL **NS**, D5W[174] (do not dilute to less than 0.1 mg/mL)[174]	24 h **F**, RT[174]	- for LYEPOCHR protocol, see entry for EPOCHR (3-in-1 solution containing either etoposide or etoposide phosphate AND DOXOrubicin and vinCRIStine)
	10 mL NS, D5W, SWI, BWI[174]	10 mg/mL[174]				
Filgrastim (NEUPOGEN®) 300 mcg/1 mL 480 mcg/1.6 mL (Amgen) (F)(PFL) do not shake no preservative[175]	N/A	300 mcg/mL[175]	discard unused portion[175]	SC syringe[175]	10 d F[2,176]	- albumin is added to D5W to prevent filgrastim adsorption to plastic[175] - incompatible with saline[175,177] - do NOT dilute to less than 5 mcg/mL[175]
				50-100 mL **D5W** only[177] in PVC, polyolefin, or glass[175] (for filgrastim concentrations of 5-15 mcg/mL in D5W, add albumin 2 mg/mL)[175]	7 d F[176]	

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Fludarabine 50 mg (Accord) (F) no preservative[178]	N/A	25 mg/mL[178]	discard unused portion[178]	dilute to maximum of 1 mg/mL **NS**, D5W[178] 100 mL†	72 h F, 24 h RT[178]	
Fludarabine 50 mg (Teva) (F) no preservative[179]	N/A	25 mg/mL[179]	discard unused portion[179]	dilute to maximum of 1 mg/mL **NS,** D5W[179] 100 mL†	72 h F, 24 h RT[179]	

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Fluorouracil 5000 mg/100 mL (Accord) (RT)(PFL) no preservative[180]	N/A	50 mg/mL[180]	12 h RT[2,181]	syringe[180]	4 d RT[181]	
				0.5-10 mg/mL **D5W**[181] 500 mL†	4 d RT[181]	
				CIVI: ambulatory pump[182]	complete within 8 d[181]	
Fluorouracil 500 mg/10 mL 5000 mg/100 mL (Sandoz) (RT)(PFL) no preservative[183]	N/A	50 mg/mL[183]	12 h RT[2,184]	syringe	4 d RT[2,184]	
				0.35-15 mg/mL **D5W**[184] 500 mL†	10 d F, 4 d RT[2,184]	
				CIVI: ambulatory pump[182]	complete within 8 d[185-187]	

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Gemcitabine 1000 mg 2000 mg (Accord) (RT) no preservative[188]	1000 mg: 25 mL NS[188] 2000 mg: 50 mL NS[188]	38 mg/mL[188]	12 h RT[2,188] refrigeration may cause crystallization[188]	syringe[188]	24 h RT[2,188]	
				0.1-38 mg/mL NS[188] 250 mL†	4 d RT[2,189,190]	
Gemcitabine **<u>intravesical</u>** 1000 mg 2000 mg (Accord) (RT) no preservative[188]	1000 mg: 25 mL NS[188] 2000 mg: 50 mL NS[188]	38 mg/mL[188]	12 h RT[2,188] refrigeration may cause crystallization[188]	syringe dilute with NS to final volume of 45-90 mL[126,127,191-193]	up to 38 mg/mL[2,188] 24 h RT	
Gemcitabine 200 mg/5.3 mL 1000 mg/26.3 mL 2000 mg/52.6 mL (Pfizer/Hospira) (F) no preservative[193]	N/A	38 mg/mL[193]	discard unused portion[193]	syringe[193]	0.1-26 mg/mL: 10 d F, 24 h RT **(PFL)[2,194,195] 27-38 mg/mL: 24 h RT[195]	
				0.1–38 mg/mL **NS**, D5W[193] 250 mL†		

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Gemcitabine **intravesical** 200 mg/5.3 mL 1000 mg/26.3 mL 2000 mg/52.6 mL (Pfizer/Hospira) (F) no preservative[193]	N/A	38 mg/mL[193]	discard unused portion[193]	syringe dilute with NS to final volume of 45-90 mL[126,127,191-193]	0.1-26 mg/mL: 10 d F, 24 h RT **(PFL)[2,194,195] 27-38 mg/mL: 24 h RT[195]	
Gemcitabine (NOTE: concentration) 200 mg/5 mL 1000 mg/25 mL 2000 mg/50 mL (Sandoz) (F) no preservative[196]	N/A	**40** mg/mL[196]	discard unused portion[196]	syringe[196] 0.1–40 mg/mL **NS**, D5W[196] 250 mL†	1-25 mg/mL: 10 d F, 4 d RT[2,196,197] 26-40 mg/mL: 24 h RT[196]	**CAUTION: alternative concentration**
Gemcitabine (NOTE: concentration) **intravesical** 200 mg/5 mL 1000 mg/25 mL 2000 mg/50 mL (Sandoz) (F) no preservative[196]	N/A	**40** mg/mL[196]	discard unused portion[196]	syringe dilute with NS to final volume of 45-90 mL[126,127,191-193]	1-25 mg/mL: 10 d F, 4 d RT[2,196,197] 26-40 mg/mL: 24 h RT[196]	**CAUTION: alternative concentration**

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Gemtuzumab ozogamicin 4.5 mg (Pfizer) (F)(PFL) no preservative[198]	5 mL SWI[198] allow vial to come to RT prior to use (~5 min)[198] swirl gently to mix; do NOT shake[198]	1 mg/mL[198]	6 h F**,** 3 h RT[198] protect from light if not used immediately[198]	0.075-0.234 mg/mL **NS**[198] 25-50 mL† mix by gentle inversion; do NOT shake[198]	complete administration within 12 h F, 6 h RT[198] (PFL)** if refrigerated, bring bag to RT over 1 h prior to administration[198]	- administer with 0.2 micron in-line filter[198] - protect infusion **bag** from light (including UV) for administration[198] - protect administration **line** from light ONLY if hang time will be longer than 2 h[198,199] - solution may contain white particulates which do not affect product quality[198]
IDArubicin PFS 5 mg/5 mL 10 mg/10 mL 20 mg/20 mL (Pfizer) (F)(PFL) no preservative[200]	N/A	1 mg/mL[200]	discard unused portion[200] **(PFL)[200]	syringe[200]	use within 4 h from initial puncture[200,201]	- avoid alkaline solutions[200]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Ifosfamide 1000 mg 3000 mg (Baxter) (RT) no preservative[202]	1000 mg: 20 mL SWI[202] 3000 mg: 60 mL SWI[202] shake well	50 mg/mL[202]	12 h **F,** RT[2,203]	0.6-20 mg/mL **NS**, D5W, Lactated Ringer's[202] 500 mL†	72 h F, 24 h RT[203] 24 h **F,** RT when mixed with mesna[71]	
Ifosfamide 1000 mg 3000 mg (Fresenius Kabi) (RT) no preservative[204]	1000 mg: 20 mL SWI[204] 3000 mg: 60 mL SWI[204] shake well	50 mg/mL[204]	12 h **F,** RT[2,205]	0.6-20 mg/mL **NS,** D5W, Lactated Ringer's[204] 500 mL†	72 h F, 24 h RT[205] 24 h **F,** RT when mixed with mesna[71]	

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Iniparib 100 mg/10 mL (sanofi-aventis) (F) no preservative[206] (SAP)	N/A	10 mg/mL[206]	discard unused portion[206]	250 mL **NS**, D5W dilute to 250 mL final volume by withdrawing volume from bag equal to volume of drug to be added[206] (OR may also use empty IV bag and qs to final volume of 250 mL with **NS**, D5W[206])	24 h RT[206]	
Inotuzumab ozogamicin 0.9 mg (Pfizer) (F)(PFL) no preservative[207]	4 mL **SWI**[207] gently swirl vial to mix[207]	0.25 mg/mL[207] record time of reconstitution	4 h **F**[207] dilute dose within 4 h of reconstitution[207] protect from light if not used immediately[208]	0.01-0.1 mg/mL **NS**[207] 25-50 mL† mix by gentle inversion[207]	complete administration within 8 h of reconstitution **F,** RT[207] (PFL)[207] if refrigerated, bring bag to RT over 1 h prior to administration[207]	- do NOT shake[207] - protect container from UV and fluorescent light during storage and administration[207,208] - protect administration line from light ONLY if hang time will be longer than 1 h[207,208]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Ipilimumab 50 mg/10 mL 200 mg/40 mL (BMS Canada) (F)(PFL) no preservative[209]	N/A	5 mg/mL[209]	12 h F, RT[2,210]	1-4 mg/mL **NS**, D5W[209] 25-250 mL† OR undiluted in empty viaflex bag or glass bottle (allow vials to stand at RT for ~5 min prior to withdrawal of contents)[209]	24 h **F**, RT[210]	- do NOT shake[209] - administer with 0.2 micron in-line filter[209] - vials may contain translucent-to-white amorphous particles[209] - discard if cloudy or has pronounced colour change (should be clear to pale yellow)[209]
Irinotecan 40 mg/2 mL 100 mg/5 mL 500 mg/25 mL (Accord) (RT)(PFL) no preservative[211]	N/A	20 mg/mL[211]	discard unused portion[211]	0.12-3.0 mg/mL **D5W** (preferred), NS[211] 250-500 mL†	48 h F, 24 h RT **(PFL)[211]	

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Irinotecan 40 mg/2 mL 100 mg/5 mL 300 mg/15 mL 500 mg/25 mL (Auro) (RT)(PFL) no preservative[212]	N/A	20 mg/mL[212]	discard unused portion[212]	0.12-3.0 mg/mL **D5W** (preferred), NS[212] 250-500 mL†	10 d F, 4 d RT[2,212] **(PFL)[212] **if NOT protected from light:** 72 h RT[212]	
Irinotecan 40 mg/2 mL 100 mg/5 mL 300 mg/15 mL 500 mg/25 mL (Eugia) (RT)(PFL) no preservative[213]	N/A	20 mg/mL[213]	discard unused portion[213]	0.12-3.0 mg/mL **D5W** (preferred), NS[213] 250-500 mL†	10 d F, 4 d RT[2,213] **(PFL)[213] **if NOT protected from light[213]:** 72 h RT	
Irinotecan 40 mg/2 mL 100 mg/5 mL 300 mg/15 mL 500 mg/25 mL (Pfizer/Hospira) (RT)(PFL) no preservative[214]	N/A	20 mg/mL[214]	discard unused portion[214]	0.12-3.0 mg/mL **D5W** (preferred), NS[214] 250-500 mL†	10 d F, 4 d RT[2,214] **(PFL)[214] **if NOT protected from light:** 72 h RT[214]	

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Irinotecan liposome 43 mg/10 mL (Servier) (F)(PFL) no preservative[215]	N/A	4.3 mg/mL[215]	discard unused portion[215]	to a final volume of 500 mL **NS**, D5W[215] mix by gentle inversion[215]	24 h F, 4 h RT[215] **(PFL) if refrigerated, bring bag to RT prior to administration[215]	- do not use in-line filter[215] - **expressed as irinotecan free base**
Isatuximab 100 mg/5 mL 500 mg/25 mL (sanofi-aventis) (F)(PFL) do not shake no preservative[216]	N/A	20 mg/mL[216] inspect vial and discard if discolouration or visible particles are present[216]	discard unused portion[216]	250 mL **NS**, D5W[216] mix by gentle inversion; do NOT shake[216]	48 h F plus an additional 8 h RT including infusion time[216]	- administer with a 0.2 micron in-line filter[216]

Activation Date: 2 March 2006
Revised Date: 3 April 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Ixabepilone 15 mg (contains 16 mg) 45 mg (contains 47 mg) (BMS) (F)(PFL) no preservative[217] (SAP)	15 mg: 8 mL diluent (supplied)[217] 45 mg: 23.5 mL diluent (supplied)[217]	2 mg/mL[217]	1 h RT[217]	0.2-0.6 mg/mL Lactated Ringer's[217]	6 h RT[217]	- use non-DEHP bag and administration set[217] - administer with 0.2 micron in-line filter[217]

* Suggested volume based on usual dose range and any concentration range of stability data
† see BC Cancer IV Bag Selection table: standardized bag sizes are provided for select Benefit Drugs with concentration-dependent stability or large drug volume
** Protect from light means minimizing exposure to direct sunlight over a *storage* period. More specific information on protection from light (eg, protecting container and tubing *during administration*) will be indicated in the Special Precautions/Notes column.
*** Contains DMA (N,N dimethylacetamide). Product may be incompatible with closed system transfer devices (CSTD) such as ChemoLock.

Centres are not to change content locally. All suggestions for change are to be forwarded to the Cancer Drug Manual editor.

Explanatory Notes:

***Stability** data* assumes products prepared using standard aseptic technique in biological safety cabinet at low risk for contamination according to the classification outlined in USP 797.[218,219]
***Vial stability*:** Stability of solution after first puncture or reconstituted solution.
***Storage temperature**:* If information states same stability with refrigerator and room temperature storage, then fridge stability is bolded as preferred (ie, to minimize growth of micro-organisms).
***Discard unused portion*:** Unused portion from single use vials should be discarded at the end of the day.
"overfill known" is stated if the manufacturer states overfill that is present is within acceptable limits.
"Complete administration within __" is stated if the manufacturer specifies that the infusion must be completed in a specific time frame following preparation, usually including entire time required for preparation (from first puncture), storage, and administration of infusion.
Nomenclature for ***In-line filters*** has been standardized in the chart to 0.2 micron filter size. For more information, refer to CDM drug monograph.

Activation Date: 2 March 2006
Revised Date: 3 April 2024

Abbreviations:

BWI = bacteriostatic water for injection
CIVI: ambulatory pump = Continuous Intravenous Infusion (e.g., elastomeric infusor)
CSTD = closed system transfer device
D5W = dextrose 5% in water
DMA = N,N dimethylacetamide
F = refrigerate
Non-DEHP = not containing Di(2-ethylhexyl) phthalate (DEHP)
NS = normal saline
PES = polyethersulfone
PFL = protect from light
RT = room temperature
SAP = drug is approved for use through the Health Canada Special Access Program
SWI = sterile water for injection

References:

1. SteriMax Inc. PROLEUKIN® product monograph. Oakville, Ontario; July 6 2020
2. BC Cancer. Provincial Pharmacy Directive Number II-20: Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer; May 1 2022
3. McEvoy GK, editor. AHFS 2008 Drug Information. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc.; . p. 917-925
4. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011;365(22):2055-2066
5. Koreth J, Alyea EP, Cutler C, Ho VT, et al. Clinical Study Protocol: A phase I study of ultra-low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease. Boston, MA, USA: Dana Farber Cancer Institute; Harvard Medical Centre; 14 Dec 2010
6. Temple-Oberle CF, Byers BA, Hurdle V, et al. Intra-lesional interleukin-2 for in-transit melanoma. J Surg Oncol 2014;109(4):327-331
7. BC Cancer Skin and Melanoma Tumour Group. (SMILALD) BC Cancer Protocol Summary for Treatment of In-Transit Melanoma Using Intralesional Aldesleukin (IL-2). Vancouver, British Columbia: BC Cancer; 1 August 2021
8. Rui Paiva. Business Unit Director, Transplant and Oncology. Personal communication. 1 June2009
9. Bayer HealthCare Pharmaceuticals. MabCampath® Package Insert. Toronto, Ontario; 1 September 2007
10. Lundin J, Porwit-MacDonald A, Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004(18):484-490
11. Berlex Canada Inc. Campath Drug Information. San Antonio, Texas; undated undated
12. Neijssen J, Cardoso RMF, Chevalier KM, et al. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. J Biol Chem 2021;296(100641):1-13
13. Eric Li, Manager Special Access Program, Janssen Inc. Personal Communication. November 18,2021
14. Janssen Biotech Inc. RYBREVANT® full prescribing information. Horsham, PA, USA; May 2021
15. Janssen Inc. RYBREVANT® product monograph. Toronto, Ontario; March 30, 2022
16. Erfa Canada Inc. AMSA PD® injection product monograph. Westmount, Quebec; 16 August 2005
17. Phebra Pty Inc (distributed in Canada by ICON Plc). Arsenic trioxide product monograph. Dundas, Ontario; November 7, 2019
18. Sandoz Canada Inc. Arsenic trioxide for injection product monograph. Boucherville, Quebec; March 8, 2021
19. SteriMax Inc. Arsenic Trioxide product monograph. Oakville, Ontario; September 27, 2019
20. CGF Pharmatec for Jazz Pharmaceuticals France SAS. ERWINASE® product monograph. Montreal, Quebec; August 30 2016

21. Hoffmann-La Roche Limited. TECENTRIQ® product monograph. Mississauga, Ontario; 19 September 2019
22. EMD Serono. BAVENCIO® product monograph. Mississauga, Ontario; 4 May 2018
23. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 19 September 2007
24. Celgene Inc. VIDAZA® product monograph. Mississauga, Ontario; 22 March 2018
25. Tutino A, Lai M. Cold water reconstitution of Vidaza with subsequent refrigerated storage prolongs drug stability. Eur J Oncol Pharm 2011;5(3-4):24-25, 34
26. Celgene Corporation. VIDAZA® full prescribing information. Summit, New Jersey, USA; May 2022
27. Dr. Reddy's Laboratories Limited. Azacitidine for injection product monograph. Mississauga, Ontario; 19 April 2017
28. Hikma Canada Inc. Azacitidine for injection product monograph. Caledon, Ontario; November 6, 2020
29. Merck Canada Inc. OncoTICE® product monograph. Kirkland, Quebec; 29 April 2019
30. BC Cancer. Provincial Pharmacy Directive Number II-20: Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer; December 5 2018
31. Verity Pharmaceuticals Inc. VERITY-BCG® Product Monograph. Mississauga, Ontario; 5 January 2021
32. GlaxoSmithKline. Belantamab mafodotin (GSK2857916) Investigational Product Information for Compassionate Use - Version 5.0. Collegeville, Pennsylvania, USA; 25 September 2019
33. GlaxoSmithKline. Belantamab mafodotin (GSK2857916) LYOPHILIZED POWDER Investigational Product Information for Compassionate Use - Version 1. Collegeville, Pennsylvania, USA; 26 October 2020
34. GlaxoSmithKline. BLENREP® full prescribing information. Research Triangle Park, North Carolina, USA; August 2020
35. Spectrum Pharmaceuticals Inc. BELEODAQ® full prescribing information. Irvine, CA, USA; April 2012
36. Natco Pharma Canada Inc. NAT-Bendamustine product monograph. Mississauga, ON; March 4, 2020
37. Teva Canada Limited. TREANDA® product monograph. Toronto, Ontario; 10 January . 2018
38. Lundbeck Canada Inc. TREANDA® product monograph. Montreal, Quebec; 22 August . 2012
39. Hoffman-La Roche Limited. AVASTIN® product monograph. Mississauga, Ontario; 6 June 2018
40. Amgen Canada Inc. MVASI® product monograph. Mississauga, Ontario; 5 June 2019
41. Pfizer Canada-ULC. ZIRABEV® product monograph. Kirkland, Quebec; June 17 2021
42. Fresenius Kabi Canada Ltd. Bleomycin for injection product monograph. Richmond Hill, Ontario; 1 June . 2016
43. Pfizer Canada Inc. Bleomycin for Injection product monograph. Kirkland, Quebec; 8 August 2017
44. Amgen Canada Inc. BLINCYTO® product monograph. Mississauga, Ontario; 12 July . 2016
45. Amgen Canada Inc. BLINCYTO® product monograph. Mississauga, Ontario; May 6, 2021
46. Actavis Pharma Company. ACT BORTEZOMIB® Bortezomib for injection product monograph. Mississauga, Ontario; 24 September 2015
47. Law S, Charbonneau LF, Iazzeta J, et al. Stability of generic formulations of bortezomib 1.0 and 2.5 mg/mL in vials and syringes stored at 4˚C and room temperature (23˚C). CJHP Canadian Society of Hospital Pharmacists Professional Practice Conference 2018 Poster Abstracts.Feb 4 - 6, 2018
48. Apotex Inc. Bortezomib for injection product monograph. Toronto, Ontario; 15 February 2019
49. Walker SE, Law S, Ma N. (Abstract) Stability of 1.0 and 2.5 mg/mL bortezomib solution in vials and syringes following reconstitution with 0.9% sodium chloride at 4ºC and room temperature (25ºC). (Apotex brand). Department of Pharmacy, Sunnybrook Health Sciences Centre and Leslie Dan Faculty of Pharmacy, University of Toronto. Toronto, ON 2019
50. Janssen Inc. VELCADE® product monograph. Toronto, Ontario; 20 June 2013
51. Juno Pharmaceuticals Corp. Bortezomib for injection product monograph. Mississauga, Ontario; 23 Jun 2020
52. Law S, Charbonneau F, Iazzeta J, et al. Stability of generic formulations of bortezomib 1.0 and 2.5 mg/mL in vials and syringes stored at 4˚C and room temperature (23˚C or 25˚C). CJHP 2021;74(1):57-69
53. Marcan Pharmaceuticals Inc. Bortezomib product monograph. Ottawa, Ontario; October 17, 2019
54. MSN Laboratories Private Limited, Formulations Division - Nandigama. Reconstitution Study Report for Bortezomib for Injection 3.5 mg vial (Reference Protocol No SSP-CL011-003-00) . 2016:1-8
55. Suresh Arvapalli. Director - Technical. Marcan Pharmaceuticals Inc. Personal communication - extended stability study on Bortezomib for Injection 3.5 mg. August 92021
56. Pharmascience Inc. pms-BORTEZOMIB product monograph. Montréal, Quebec; March 8, 2019
57. Taro Pharmaceuticals Inc. Taro-Bortezomib product monograph. Brampton, Ontario; October 27, 2021
58. Teva Canada Limited. Bortezomib for injection® product monograph. Toronto, Ontario; 22 January 2015
59. Seagen Canada Inc. ADCETRIS® product monograph. Mississauga, Ontario; June 11 2021
60. Pharmascience Inc. Busulfan for injection product monograph. Montreal, Quebec; 14 June 2018

61. SteriMax Inc. Busulfan for injection product monograph. Oakville, Ontario; 4 May 2017
62. Dr. Reddy's Laboratories Canada Inc. Cabazitaxel for injection product monograph. Mississauga, Ontario; January 14, 2020
63. Sandoz Canada Inc. Cabazitaxel for injection product monograph. Boucherville, Quebec; 17 December . 2019
64. sanofi-aventis Canada Inc. JEVTANA® product monograph. Laval, Quebec; 7 September . 2017
65. Accord Healthcare Inc. Carboplatin injection® product monograph. Kirkland, Quebec; 15 May 2019
66. Omega Laboratories Ltd. Carboplatin injection product monograph. Montreal, Quebec; 24 March . 2011
67. Nayla El Zir. Associate, Regulatory Affairs, Omega Laboratories Limited. Personal communication. 12 April2017
68. Pfizer Canada-ULC. Carboplatin injection product monograph. Kirkland, Quebec; 31 December 2018
69. Novopharm Limited. Carboplatin Package Insert. Toronto, Canada; Undated Undated
70. Manjinder S Kang. Regulatory Affairs Drug Information Pharmacist, Novopharm Canada. Personal communication. 14 March2005
71. Trissel LA. Handbook on Injectable Drugs. 13th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2005
72. Repchinsky C editor. Paraplatin-AQ, Compendium of Pharmaceuticals and Specialties. 12th ed. Ottawa, Ontario: Canadian Pharmacists Association; 2004
73. BC Cancer Provincial Pharmacy Professional Practice Council. BC Cancer Provincial Pharmacy Professional Practice Council meeting minutes . April 13,2022
74. Amgen Canada Inc. KYPROLIS® product monograph. Mississauga, Ontario; January 27, 2021
75. Luis Simao. Area Manager, ICU Medical Canada. Personal communication. 11 May2018
76. Amgen Canada Inc. KYPROLIS® product monograph. Mississauga, Ontario; 6 July 2017
77. Diane Lord. Medical Information, Amgen Canada Inc. Personal communication. 8 May2018
78. SteriMax Inc. Carmustine for Injection product monograph. Oakville, Ontario; October 11, 2022
79. sanofi-aventis Canada Inc. LIBTAYO® product monograph. Laval, Quebec; 10 April 2019
80. ImClone LLC (distributed by Eli Lilly Canada Inc). ERBITUX® product monograph. Toronto, Ontario; January 10, 2018
81. Accord Healthcare Inc. Cisplatin injection product monograph. Kirkland, Quebec; February 15 2019
82. Pfizer Canada-ULC. Cisplatin injection product monograph. Kirkland, Quebec; December 7 2018
83. Sandoz Canada Inc. Cisplatin Injection BP product monograph. Boucherville, Quebec; 13 April . 2011
84. Sandoz Canada Inc. Cisplatin Injection BP product monograph. Boucherville, Quebec; September 28 2015
85. Teva Canada Limited. Cisplatin injection product monograph. Toronto, Ontario; March 6 2013
86. Fresenius Kabi Canada Ltd. Cladribine injection® product monograph. Richmond Hill, Ontario; 9 June 2015
87. BC Cancer Lymphoma Tumour Group. (LYCDA) BC Cancer Protocol Summary for Treatment of Hairy Cell Leukemia with Cladribine. Vancouver, British Columbia: BC Cancer; 1 January 2021
88. Myrna O'Brodovich. Senior Medical Information Associate, Ortho Biotech. Personal communication. 2 April2008
89. de Lemos ML, Hamata L. Stability issues of parenteral chemotherapy drugs. J Oncol Pharm Pract 2007;13(1):27-31
90. Generic Medical Partners Inc. Cladribine injection product monograph. Toronto, Ontario; December 3 2019
91. Jazz Pharmaceuticals Canada Inc. RYLAZE® product monograph. Mississauga, Ontario; September 2, 2022
92. Baxter Corporation. PROCYTOX® product monograph. Mississauga, Ontario; 7 September 2012
93. Baxter Corporation Medical Information. Personal communication. 14 May2020
94. Baxter Healthcare Corporation. Cyclophosphamide for injection full prescribing information. Deerfield, Illinois USA; May 2013
95. Trissel's® 2 Clinical Pharmaceutics Database - Lexicomp Online (database on the Internet). Cyclophosphamide. Wolters Kluwer Clinical Drug Information Inc., undated. Available at: http://online.lexi.com. Accessed 14 May, 2020
96. Pfizer Canada Inc. Cytarabine Solution for Injection product monograph. Kirkland, Quebec; 3 November 2015
97. BC Cancer Lymphoma Tumour Group. (LYIT) BC Cancer Protocol Summary for Treatment of Lymphoma using Intrathecal Methotrexate and Cytarabine. Vancouver, British Columbia: BC Cancer; 1 June 2014
98. BC Cancer Miscellaneous Origin Tumour Group. (MOIT) BC Cancer Protocol Summary for Solid Tumours using Intrathecal Methotrexate and/or Thiotepa and/or Cytarabine. Vancouver, British Columbia: BC Cancer; 1 October 2018
99. BC Cancer. Systemic Therapy Policy and Procedure III-50: Administration of High Alert Medications by the Intrathecal Route via Lumbar Puncture or Ommaya Reservoir. Vancouver, British Columbia; May 1 2019
100. Hematology/Oncology Pharmacy Association. HOPA News Clinical Pearls: Intrathecal Chemotherapy: Focus on Drugs, Dosing, and Preparation. 13(4) ed. Chicago, Illinois, USA: Hematology/Oncology Pharmacy Association; 2016

101. BC Cancer Agency - Provincial Pharmacy Professional Practice Council. Minutes of The Provincial Pharmacy Professional Practice Council (P4C) Meeting. Vancouver, British Columbia: BC Cancer; Feb 5, 2014
102. Astier A, Pinguet F, Vigneron J. The practical stability of anticancer drugs: SFPO and ESOP recommendations. Eur J Oncol Pharm 2010;4:4-10
103. Dellamorte Bing C, Nowobilski-Vasilios A. Extended Stability for Parenteral Drugs. 5th ed. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc; 2013
104. Pharmascience Inc. Cytarabine Solution for Injection product monograph. Montreal, Quebec; 14 February 2017
105. SteriMax Inc. Cytarabine injection product monograph. Oakville, Ontario; April 19, 2021
106. Pfizer Canada Inc. Dacarbazine for Injection product monograph. Kirkland, Quebec; 31 May 2018
107. Trissel L. Handbook on injectable drugs. 13th ed. Bethesda, Maryland: American Society of Health-System Pharmacists; 2005. p. 428-431
108. Recordati Rare Diseases Inc. COSMEGEN® product monograph. Lebanon, New Jersey USA; 24 July 2014
109. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 19 September 2007
110. Andy Harbrow.Global Medical Services Manager, Primevigilance (for Recordati Rare Diseases Inc.). Personal communication: dactinomycin solutions for infusion. 15 July2014
111. Janssen Inc. DARZALEX® product monograph. Toronto, Ontario; 29 June 2016
112. Janssen Inc. DARZALEX® SC product monograph. Toronto, Ontario; June 22, 2022
113. ERFA Canada Inc. CERUBIDINE® product monograph. Montréal, Quebec; August 2, 2017
114. ERFA Canada Inc. Daunorubicin product monograph. Montreal, Quebec; August 15 2012
115. Jazz Pharmaceuticals Canada Inc. VYXEOS® product monograph. Mississauga, Ontario; April 28, 2021
116. Ferring Pharmaceuticals. FIRMAGON® product monograph. North York, Ontario; 20 March . 2013
117. Ferring Pharmaceuticals. FIRMAGON® product monograph. North York, Ontario; 06 November . 2009
118. Amgen Canada Inc. XGEVA® product monograph. Mississauga, Ontario; 14 October . 2011
119. Mike Armstrong. Canada Country Director. Hikma Canada Limited. Importation of US-labelled Dexrazoxane for Injection due to the current shortage of Canadian-authorized Dexrazoxane for Injection. Mississauga, Ontario; March 24, 2023
120. Hikma Pharmaceuticals USA Inc. Dexrazoxane for Injection full prescribing information. Berkeley Heights, New Jersey, USA; December 2018
121. Pfizer Canada Inc. ZINECARD® product monograph. Kirkland, Quebec; March 30 2015
122. Unither Biotec Inc. for United Therapeutics Corp. UNITUXIN® product monograph. Magog, Quebec; 28 November 2018
123. Pfizer Canada-ULC. Docetaxel injection product monograph. Kirkland, Quebec; 26 March 2021
124. Josee Lloyd. Senior Clinical Specialist, Hospira Clinical Support Team, Hospira Healthcare Corporation. Personal communication: multidose vials and venting needles. 13 July2011
125. Hospira Canada Clinical Support Team, Hospira Canada Healthcare Corporation. Personal communication. 21 March2011
126. Steinberg RL, Thomas LJ, Brooks N, et al. Multi-institution evaluation of sequential intravesical gemcitabine and docetaxel as rescue therapy for non-muscle invasive bladder cancer. J Urol 2020;203(5):902-909
127. BC Cancer Genitourinary Tumour Group. (GUBGEMDOC) BC Cancer Protocol Summary for Intravesical Therapy for Non-Muscle Invasive Bladder Cancer Using Gemcitabine and Docetaxel. Vancouver, British Columbia: BC Cancer; 1 August 2021
128. Sandoz Canada Inc. Docetaxel injection product monograph. Boucherville, Quebec; 17 November 2020
129. Bazundama Bazuta Feza Sandrine. Medical Information Intern, Sandoz Canada Inc. Personal communication: in-house vial stability for docetaxel injection. 14 August2018
130. Bazundama Bazuta Feza Sandrine. Medical Information Intern, Sandoz Canada Inc. Personal communication: in-house product stability of diluted docetaxel injection. 14 August2018
131. Vigneron J, Astier A, Trittler R, et al. SFPO and ESOP recommendations for the practical stability of anticancer drugs: an update. Ann Pharm Fr 2013;71(6):376-389
132. Trissel's® 2 Clinical Pharmaceutics Database - Lexicomp Online (database on the Internet). Docetaxel. Wolters Kluwer Clinical Drug Information Inc., undated. Available at: http://online.lexi.com. Accessed 7 July, 2021
133. Accord Healthcare Inc. Doxorubicin injection® product monograph. Montreal, Quebec; 9 April 2014
134. Trissel's® 2 Clinical Pharmaceutics Database - Lexicomp Online (database on the Internet). Doxorubicin. Wolters Kluwer Clinical Drug Information Inc., undated. Available at: http://online.lexi.com. Accessed March 23, 2023
135. Trissel's®2 IV Compatibility (database on the Internet). Doxorubicin. Merative MICROMEDEX® 2.0, undated. Available at: http://www.micromedex.com. Accessed March 23, 2023
136. Gerrie AS, Mikhael JR, Cheng L, et al. D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma. Br J Haematol 2013;161(6):802-810

137. Lee C, Barlogie B, Munshi N, et al. DTPACE: An Effective, Novel Combination Chemotherapy With Thalidomide for Previously Treated Patients With Myeloma. J Clin Oncol 2003;21(14):2732-2739
138. BC Cancer Myeloma Tumour Group. (UMY0 [D-PACE]) BC Cancer Interim Treatment Plan for ULY0 CAP 112919 (Treatment of Myeloma with CISplatin, Etoposide, DOXOrubicin, Cyclophosphamide and Dexamethasone). Vancouver, British Columbia: BC Cancer; April 1 2023
139. Novopharm Limited. Doxorubicin Product Monograph. Scarborough, Ontario; 8 November 1996
140. Pfizer Canada Inc. ADRIAMYCIN® injection product monograph. Kirkland, Quebec; 28 August . 2007
141. Janssen Inc. CAELYX® product monograph. Toronto, Ontario; 10 October 2013
142. Taro Pharmaceuticals Inc. Taro-DOXOrubicin Liposomal product monograph. Brampton, Ontario; 7 October 2019
143. Trissel's® 2 Clinical Pharmaceutics Database - Lexicomp Online (database on the Internet). CISplatin + CycloPHOSphamide - Admixture compatibility/ Study 1 /Note. Wolters Kluwer Clinical Drug Information Inc., undated. Available at: http://online.lexi.com. Accessed March 9, 2023
144. Trissel's®2 IV Compatibility (database on the Internet). Cisplatin and cyclophosphamide admixture compatibility. Merative MICROMEDEX® 2.0, undated. Available at: http://www.micromedex.com. Accessed March 9, 2023
145. AstraZeneca Canada Inc. IMFINZI® product monograph. Mississauga, Ontario; October 25 2023
146. McInerney M, Suess J. SBAR: Preparation of Durvalumab Vials without ChemoLock®. Approved by BC Cancer Provincial Pharmacy Professional Practice Committee. 2023
147. Pfizer Canada-ULC. ELREXFIO® product monograph. Kirkland, Québec; December 6, 2023
148. Pfizer Inc and Affiliates Global Product Development. PF-06863135 Solution for Subcutaneous Injection (40 mg/mL) Investigational Product Manual Version 1.0. New York, NY; December 7, 2021
149. Hicham Gonzalez. Medical Liaison. Pfizer Canada Oncology. Personal Communication. March 29,2023
150. Michelle Koberinski. BC Cancer Oncology Certification Pharmacy Technician. Personal Communication - Elranatamab. May 30,2023
151. Seagen Canada Inc. PADCEV® product monograph. Mississauga, Ontario; October 29 2021
152. AbbVie Corporation. EPKINLY® product monograph. St-Laurent, Quebec; October 13, 2023
153. AbbVie Inc. Investigative Site Pharmacy Manual for Protocol M20-638 (EPCORETM FL-1): Investigational Product Preparation and Administration Instructions for Epcoritamab (ABBV-GMAB-3013). Version 2.0. North Chicago, Illinois, USA; August 5, 2022
154. Novopharm. Epirubicin for Injection product monograph. Toronto, Ontario; 16 March . 2009
155. Pharmaceutical Partners of Canada, Inc. Epirubicin Hydrochloride Injection product monograph. Richmond Hill, Ontario; 6 July . 2010
156. Pharmacia Canada Inc. Pharmorubicin PFS Package Insert. Mississauga, Ontario; May 2003
157. Trissel LA. Handbook on Injectable Drugs. 12th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2003
158. BC Cancer Agency Lymphoma Tumour Group. (ULYEPOCHR) Interim BCCA Protocol Summary for Treatment of Lymphoma with Dose-Adjusted Etoposide, DOXOrubicin, VinCRIStine, Cyclophosphamide, PredniSONE, and riTUXimab (LYEPOCHR) with Intrathecal Methotrexate. Vancouver, British Columbia: BC Cancer Agency; 1 July 2015
159. Barry Goldspiel. NIH Clinical Centre. Personal communication: EPOCHR. 14 April2015
160. Wolfe JL, Thoma LA, Du C, et al. Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium chloride injection. Am J Health-Syst Pharm 1999;56:985-989
161. Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med 2013;369:1915-1925
162. Yuan P, Grimes GJ, Shankman SE, et al. Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide phosphate in 0.9% sodium chloride injection. Am J Health-Syst Pharm 2001;58(7):594-598
163. BC Cancer Lymphoma Tumour Group. (LYEPOCHR) BC Cancer Protocol Summary for Treatment of Lymphoma with Dose Adjusted Etoposide, DOXOrubicin, vinCRIStine, Cyclophosphamide, predniSONE and riTUXimab with Intrathecal Methotrexate. Vancouver, British Columbia: BC Cancer; January 1 2022
164. eviQ. Cancer Institute New South Wales. NSW Government. Non-Hodgkin lymphoma DA-R-EPOCH (dose adjusted rituximab etoposide prednisolone vincristine CYCLOPHOSPHamide DOXOrubicin) - Treatment schedule overview . St Leonards NSW AustraliaSeptember 17 2022
165. Eisai Limited. HALAVEN® product monograph. Mississauga, Ontario; 17 January . 2013
166. Novopharm Limited. Etoposide Product Monograph. Toronto, Ontario; 2000
167. Lepage R, Walker S, Godin J. Stability and compatibility of etoposide in normal saline. Canadian Journal of Hospital Pharmacy 2000;53(5):338-345
168. The United States Pharmacopeial Convention, Inc. General Chapter 797: Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: The United States Pharmacopeial Convention, Inc.; 2003
169. BC Cancer Agency. Provincial Pharmacy Directive III-50-04: Management of Particulate During Sterile Preparation. Vancouver, British Columbia: BC Cancer Agency; 9 July 2014
170. Angie Chan. Drug Information Pharmacist, Novopharm. Personal communication. 29 September2006

171. Bristol-Myers Squibb Company. ETOPOPHOS® product monograph. Princeton, New Jersey, USA; March 2011
172. Joseph Atallah. Interim County Medical Director. Bristol-Myers Squibb Canada. Personal communication re: new Canadian distributor for ETOPOPHOS®. November 15,2019
173. George Gafrey. VP Business Development. Xediton Pharmaceuticals Inc. Personal communication re: new Canadian distributor for ETOPOPHOS®. November 27,2019
174. Bristol-Myers Squibb Company. ETOPOPHOS® product monograph. Princeton, New Jersey, USA; May 2019
175. Amgen Canada Inc. NEUPOGEN® product monograph. MIssissauga, Ontario; March 21 2014
176. Amgen Medical Information. Amgen Canada Inc. Personal communication. 8 July2014
177. Trissel LA. Handbook on Injectable Drugs. 13th ed. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc; 2005. p. 648-655
178. Accord Healthcare Inc. Fludarabine phosphate injection product monograph. Kirkland, Quebec; September 29, 2021
179. Teva Canada Limited. Fludarabine phosphate product monograph. Toronto, Ontario; March 1, 2016
180. Accord Healthcare Inc. Fluorouracil injection® product monograph. Kirkland, Quebec; 30 September 2013
181. Charles Vachon. Quality and Regulatory Affairs, Accord Healthcare Inc. Personal communication. 29 September2016
182. John Korontzis. Regulatory Affairs Associate, Mayne Pharma Canada. Personal communication: Fluorouracil. February 16,2005
183. Sandoz Canada Inc. Fluorouracil Injection product monograph. Boucherville, Quebec; 3 April . 2012
184. Alexandre Dussault. Drug Information & Pharmacovigilance Coordinator, Sandoz Canada Inc. Personal communication. 19 November2015
185. Trissel L. Handbook on Injectable Drugs. 13th ed. Bethesda, Maryland: American Society of Health-System Pharmacists; 2005. p. 613-622
186. BC Cancer Agency Experimental Therapeutics. Physicochemical stability analysis of fluorouracil products in final chemotherapeutic preparations. Vancouver, BC. ;Study number 50009:1-43
187. Stiles ML, Allen Jr LV, Tu YH. Stability of fluorouracil administered through four portable infusion pumps. American Journal of Hospital Pharmacy 1989;46(10):2036-2040
188. Accord Healthcare Inc. Gemcitabine injection product monograph. Kirkland, Quebec; 24 March 2020
189. Purvi Agrawal BScPharm. Regulatory Affairs Manager, Accord Healthcare Inc. Personal communication. 07 September2012
190. Astron Research LU. Gemcitabine for Injection (STBRG/ACGEM/01).
191. Skinner EC, Goldman B, Sakr WA, et al. SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical Bacillus Calmette-Guerin. J Urol 2013;190(4):1200-1204
192. BC Cancer Genitourinary Tumour Group. (GUBGEM) BC Cancer Protocol Summary for Intravesical Therapy for Non-Muscle Invasive Bladder Cancer Using Gemcitabine. Vancouver, British Columbia: BC Cancer; 1 November 2019
193. Pfizer Canada Inc. Gemcitabine Injection (ready to use solution) product monograph. Kirkland, Quebec; 25 October 2018
194. Vachon, Brigitte. Clinical Specialist, Clinical Support. Hospira Healthcare Corporation. Personal Communication: Stability of Gemcitabine Injection (Ready-to-use solution) Diluted in Solution. June 11,2015
195. Pfizer Canada-ULC. Gemcitabine injection product monograph. Kirkland, Québec; March 16, 2021
196. Sandoz Canada Inc. Gemcitabine hydrochloride solution for injection product monograph. Boucherville, Quebec; 14 August 2014
197. Bazundama Bazula Faza, Sandrine. Drug Information Coordinator. Sandoz Canada Inc. Personal Communication: Gemcitabine injection. July 22,2019
198. Pfizer Canada-ULC. MYLOTARG® product monograph. Kirkland, Quebec; 28 November 2019
199. Sharon Keane. Pfizer Canada Medical Information. Personal communication. 7July2020
200. ULC Pfizer Canada. Idarubicin hydrochloride injection product monograph. Kirkland, Quebec; September 14, 2021
201. BC Cancer Provincial Systemic Therapy Program. Provincial Systemic Therapy Program Policy III-20: Prevention and Management of Extravasation of Chemotherapy. Vancouver, British Columbia: BC Cancer; March 1 2021
202. Baxter Corporation. IFEX® product monograph. Mississauga, Ontario; 5 April 2012
203. Baxter Corporation. IFEX® product monograph. Mississauga, Ontario; June 27, 2018
204. Pharmaceutical Partners of Canada, Inc. Ifosfamide for Injection product monograph. Richmond Hill, Ontario; 17 January . 2008
205. Fresenius Kabi Canada Ltd. Ifosfamide for Injection product monograph. Toronto, Ontario; October 10, 2018
206. sanofi-aventis Canada. Iniparib (BSI-201;SAR240550) Special Access Program Guidance for the Physician. Laval, Quebec; 15December. 2010
207. Pfizer Canada Inc. BESPONSA® product monograph. Kirkland, Quebec; 15 March 2018
208. Pfizer Medical Information. Pfizer Canada Inc. Personal communication. 26 November2018
209. Bristol Myers Squibb Canada. YERVOY® product monograph. Montreal, Quebec; 1 February . 2012
210. Bristol-Myers Squibb Canada. YERVOY® product monograph. Montreal Canada; December 12, 2017
211. Accord Healthcare Inc. Irinotecan injection® product monograph. Kirkland, Quebec; 6 May 2014

212. Auro Pharma Inc. Irinotecan hydrochloride injection product monograph. Woodbridge, Ontario; June 30, 2020
213. Eugia Pharma Inc. Irinotecan hydrochloride injection product monograph. Woodbridge, Ontario; July 6 2022
214. Pfizer Canada Inc. Irinotecan hydrochloride injection product monograph. Kirkland, Quebec; 8 March 2019
215. Servier Canada Inc. ONIVYDE® product monograph. Laval, Quebec; 4 January 2019
216. sanofi-aventis Canada Inc. SARCLISA® product monograph. Laval, Quebec; October 12 2022
217. Bristol-Myers Squibb. IXEMPRA® product monograph. Princeton, New Jersey; 01 October . 2007
218. The United States Pharmacopeia, (USP). General Chapter 797: Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: The United States Pharmacopeial Convention, Inc.; 2004
219. Kastango ES. The ASHP discussion guide for compounding sterile preparations. Bethesda (MD): American Society of Health-System Pharmacists, Inc.; 2004. p. 5